美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

科興生物

6.47

0.0000

成交量：- -

成交額：- -

市值：3.89億

市盈率：6.66

高：6.47

開：6.47

低：6.47

收：6.47

52周最高：6.47

52周最低：6.47

股本：6,006.07萬

流通股本：3,116.90萬

量比：0.52

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.9710

每股收益(LYR):1.06

淨資產收益率：25.15%

總資產收益率：11.46%

市淨率：0.52

市盈率(LYR):6.13

資料載入中...

總覽公司新聞資訊公告

科興生物退市風暴：從「疫苗之王」到轟然坍塌

2025年中國生物製劑行業政策、產業鏈、市場規模、研發支出、競爭格局及未來發展趨勢研判：已成為醫藥行業增長最快的領域之一，市場規模將達到6752億元[圖]

科興生物陷退市危機，十年內鬥拖累經營與治理

停牌6年後科興生物要退市

国际金融报

科興生物再觸退市紅線治理困局拖累美股上市地位

华夏时报网

科興生物收到納斯達克退市通知；廣譽遠副總裁離任

21世纪经济报道

科興生物收到納斯達克退市通知公司回應：計劃進行聽證申辯會

每日经济新闻

科興生物人干擾素α1b吸入溶液納入突破性治療品種名單

AEO認證助力生物藥出海搶出「黃金48小時」

科興甲型乙型肝炎聯合疫苗倍爾來福再註冊上市

爭奪疫苗之王

89億美元鉅額派息背後：科興生物九年「內鬥」將如何收場？

李嘉強方面表態：探索科興生物未來在港交所上市，自己無意長期擔任董事長職位

知情人士：解決科興「內鬥」應以談為主科興生物董事長李嘉強稱尹衞東是個好CEO

【愛建醫藥】創新藥主線強勢迴歸，關注BigPharma管線價值重估

爱建证券研究所

科興生物爭奪記：誰能打開百億美元「金庫」大門？

每日经济新闻

十年內鬥未休，科興生物滑向退市

科興「宮鬥」背後，第一大股東強新資本的算盤

科興生物內鬥漩渦：九年紛爭何時落幕？又將走向何方？

21世纪经济报道

科興生物75億美元「清倉式派息」背後：十年內鬥掏空現金儲備研發停滯退市風險激增

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SVA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","market":"US","secType":"STK","nameCN":"科興生物","latestPrice":6.47,"timestamp":1764968400000,"preClose":6.47,"halted":3,"volume":0,"delay":0,"floatShares":31169000,"shares":60060702,"eps":0.971025,"marketStatus":"停牌","change":0,"latestTime":"12-05 16:00:00 EST","open":6.47,"high":6.47,"low":6.47,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.971025,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1102482000000,"exchange":"NASDAQ","adjPreClose":6.47,"volumeRatio":0.5219117885997689},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","floatShares":31169000,"roa":"11.46%","roe":"25.15%","lyrEps":1.055174,"volumeRatio":0.5219117885997689,"shares":60060702,"dividePrice":0,"high":6.47,"amplitude":0,"preClose":6.47,"low":6.47,"week52Low":6.47,"pbRate":"0.52","week52High":6.47,"institutionHeld":0.1887,"latestPrice":6.47,"eps":0.971025,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.971025,"open":6.47,"prevYearClose":6.47,"prevWeekClose":6.47,"prevMonthClose":6.47,"prevQuarterClose":6.47,"fiveDayClose":6.47,"twentyDayClose":6.47,"sixtyDayClose":6.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVA\",params:#limit:5,,,undefined,":[{"date":"2025-07-08","symbol":"SVA","amount":55,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1751981400000,"name":"科兴生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1751947200000,"payDate":"2025-07-07"},{"market":"US","date":"2022-04-29","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1651204800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-12-31","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1640926800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-09-17","symbol":"SVA","fiscalQuarterEnding":"2021/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1631851200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2021-06-29","symbol":"SVA","fiscalQuarterEnding":"2021/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1624939200000,"reportTimeType":"","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVA\",market:\"US\",,,undefined,":[{"executeDate":"2025-07-08","recordDate":"2025-05-23","paymentDate":"2025-07-07","value":55,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVA","date":"2021-09-21","current":6.663062,"percent":0.24257,"low":-100.201212,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"high":42.074882,"avg":0.136365,"sd":42.133061,"marketCap":642436987},"quantilePoints":[{"date":"2020-12-11","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-18","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-24","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2020-12-31","current":25.871431,"twenty":-59.560853,"median":24.296893,"eighty":29.948237,"marketCap":639903982},{"date":"2021-01-08","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-15","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-22","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-01-29","current":25.871431,"twenty":-60.664761,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-05","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-12","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-19","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-02-26","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-05","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-12","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-19","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-03-26","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-01","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-09","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-16","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-23","current":5.79786,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-30","current":5.82081,"twenty":-61.894113,"median":24.171596,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-07","current":5.82081,"twenty":-61.894113,"median":24.081398,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-14","current":5.82081,"twenty":-61.894113,"median":23.985687,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-21","current":5.82081,"twenty":-61.894113,"median":23.781276,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-28","current":5.82081,"twenty":-61.894113,"median":23.705864,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-04","current":5.82081,"twenty":-61.894113,"median":23.662388,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-11","current":5.82081,"twenty":-61.894113,"median":23.535556,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-18","current":5.82081,"twenty":-61.894113,"median":23.44385,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-25","current":5.82081,"twenty":-62.119913,"median":23.213593,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-02","current":5.82081,"twenty":-62.119913,"median":22.996932,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-16","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-23","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-30","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-06","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-13","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-20","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-27","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-03","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-10","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-17","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-24","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-01","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-08","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-15","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-22","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-29","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-05","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987}],"updateTime":1765070211904},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589863895","title":"科興生物退市風暴：從「疫苗之王」到轟然坍塌","url":"https://stock-news.laohu8.com/highlight/detail?id=2589863895","media":"翠鸟资本","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589863895?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 17:25","pubTimestamp":1764840304,"startTime":"0","endTime":"0","summary":"结构性缺陷埋下祸根不可否认，科兴生物曾拥有显著优势。科兴生物拥有中国最大的病毒疫苗生产基地之一、成熟的灭活技术平台、覆盖60余国的国际分销网络。疫情期间，科兴生物90%以上收入依赖新冠疫苗，利润暴涨，但缺后续发力，后续管线如带状疱疹、RSV、手足口病疫苗进展缓慢，至今无一款重磅新药上市。同时，科兴生物的战略显得较为短视。如今，科兴生物虽仍在中国境内维持部分疫苗生产，但其国际影响力几近归零。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204173617a4cc59d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204173617a4cc59d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2588947780","title":"2025年中國生物製劑行業政策、產業鏈、市場規模、研發支出、競爭格局及未來發展趨勢研判：已成為醫藥行業增長最快的領域之一，市場規模將達到6752億元[圖]","url":"https://stock-news.laohu8.com/highlight/detail?id=2588947780","media":"智研咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588947780?lang=zh_tw&edition=fundamental","pubTime":"2025-12-03 09:22","pubTimestamp":1764724920,"startTime":"0","endTime":"0","summary":"因此，全球各国加速生物制剂创新研发，市场取得快速发展。2024年，中国生物制剂市场规模从2019年的3120亿元增长至5871亿元，预计2025年中国生物制剂市场规模将达到6752亿元，预计未来五年有望达到11491亿元。预计2030年中国生物制剂的研发支出从2017年的762亿元增长至3088亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203092512a7204081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203092512a7204081&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1251922891.USD","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","02196","BK1583","BK1500","BK1588","SVA","BK1161","LU0588546209.SGD","02269","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2586204858","title":"科興生物陷退市危機，十年內鬥拖累經營與治理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586204858","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586204858?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 15:51","pubTimestamp":1764316260,"startTime":"0","endTime":"0","summary":"11月19日，科兴生物公告称收到纳斯达克上市资格部门的退市决定函，原因在于公司未能在2025年11月11日前提交2024年年度报告。尽管公司已表示将提交听证申请以暂缓退市，但这一事件再次暴露了其长期存在的公司治理问题。　　审计机构致同会计师事务所于2025年4月辞任，直接导致年报无法按时提交。　　科兴生物的退市危机，表面上是审计机构变更与年报延迟所致，实则是长期公司治理混乱、控制权争夺与经营战略失衡的集中爆发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-28/doc-infyxwfh7408453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2586290309","title":"停牌6年後科興生物要退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586290309","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586290309?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 10:22","pubTimestamp":1764210143,"startTime":"0","endTime":"0","summary":"当地时间11月24日，科兴生物公告，公司与巴西卫生部签署了两项PDP（产品开发伙伴关系）项目，在未来10年向巴西提供总计约6000万剂水痘疫苗和狂犬疫苗，价值超7亿美元（约合50亿元人民币）。据该公司介绍，这是中国疫苗企业迄今获得的最长期、合同金额最大的一笔国际订单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511273576389669.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273576389669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2585779891","title":"科興生物再觸退市紅線 治理困局拖累美股上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2585779891","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585779891?lang=zh_tw&edition=fundamental","pubTime":"2025-11-22 22:22","pubTimestamp":1763821375,"startTime":"0","endTime":"0","summary":"纳斯达克的一纸退市函，对已停牌六年的科兴生物下达了最后通牒，其美股上市地位命悬一线。因未按期提交2024年年度报告，科兴生物（NASDAQ：SVA）于2025年11月12日收到纳斯达克上市资格部门的退市决定函。若未能在规定时间内申请听证，公司股票将于11月21日起暂停交易并启动退市程序。这是自2019年因治理问题被停牌后，科兴生物面临的第二次退市危机。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511223572077338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511223572077338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2584722409","title":"科興生物收到納斯達克退市通知；廣譽遠副總裁離任","url":"https://stock-news.laohu8.com/highlight/detail?id=2584722409","media":"21世纪经济报道","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584722409?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 08:06","pubTimestamp":1763597181,"startTime":"0","endTime":"0","summary":"政策动向黄果在北京调研集采中选药品质量监管工作11月18日，国家药监局党组成员、副局长黄果在北京市调研集采中选药品质量监管工作，实地走访华润双鹤药业股份有限公司，调研企业质量管理及地方药品监管部门监管情况。黄果指出，国家药监局高度重视集采药品的质量监管，在各方持续努力下，生产供应质量整体稳定可控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511203569355255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511203569355255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TSYW.SI",".IXIC","MNQmain","BK1147","03086","BK4007","PSQ","ARTL","QID","USAW.SI","NQmain","NVIW.SI","QLD","SVA","SQQQ","USJW.SI","TQQQ","BK4139"],"gpt_icon":1},{"id":"2584717948","title":"科興生物收到納斯達克退市通知 公司回應：計劃進行聽證申辯會","url":"https://stock-news.laohu8.com/highlight/detail?id=2584717948","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584717948?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 19:26","pubTimestamp":1763551600,"startTime":"0","endTime":"0","summary":"科兴生物更新了一则关于纳斯达克退市事项的进展。公司披露的信息显示，其于2025年11月12日收到纳斯达克股票市场有限责任公司（即“纳斯达克”）上市资格部发出的退市决定函。此决定是由于公司未能遵守纳斯达克上市规则5250(c)(1)，未能在延长期限前及时提交截至2024年12月31日财年的年度报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193568947938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193568947938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MNQmain","USJW.SI","03086","QID","SQQQ","TSYW.SI","USAW.SI","SVA","PSQ","TQQQ",".IXIC","NVIW.SI","QLD","NQmain","ARTL","BK1147","BK4007","BK4139"],"gpt_icon":0},{"id":"2569799104","title":"科興生物人干擾素α1b吸入溶液納入突破性治療品種名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2569799104","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569799104?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 17:50","pubTimestamp":1758621043,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩实习记者宋雨盈）9月23日，科兴生物发布公告称，公司全资子公司深圳科兴药业有限公司自主研发的人干扰素α1b吸入溶液已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509233521320417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509233521320417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2557418563","title":"AEO認證助力生物藥出海搶出「黃金48小時」","url":"https://stock-news.laohu8.com/highlight/detail?id=2557418563","media":"大众日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557418563?lang=zh_tw&edition=fundamental","pubTime":"2025-08-06 10:37","pubTimestamp":1754447831,"startTime":"0","endTime":"0","summary":"近日，科兴制药成功通过了海关AEO高级认证审核，正式跻身海关信用管理的最高等级企业行列，成为济南市第27家高级认证企业，进军国际生物制品高端市场、服务全球患者的战略步伐更加坚实有力。AEO认证的“含金量”，正在转化为外贸高质量发展的“加速度”。今年上半年，济南市新增AEO高级认证企业3家，总数达27家，进出口值321.2亿元，占全市进出口总值比重超四成，成为推动济南外贸量稳质升不可或缺的重要力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806103955a6d59607&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806103955a6d59607&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK0239","688136","159831","159839"],"gpt_icon":0},{"id":"2555883641","title":"科興甲型乙型肝炎聯合疫苗倍爾來福再註冊上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2555883641","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555883641?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 17:36","pubTimestamp":1753954618,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2554722183","title":"爭奪疫苗之王","url":"https://stock-news.laohu8.com/highlight/detail?id=2554722183","media":"中金在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554722183?lang=zh_tw&edition=fundamental","pubTime":"2025-07-28 17:06","pubTimestamp":1753693593,"startTime":"0","endTime":"0","summary":"据说尹卫东那时决心：要做一个便宜的，中国孩子用得起的高品质疫苗。后来怡安研发的甲肝灭活疫苗获得新药证书，填补了国内空白。潘总十分赏识乡村医生尹卫东，还借给了尹卫东500万元，帮助其完成了甲肝疫苗的临床试验。2002年，甲肝灭活疫苗实现量产上市，从此中国甲肝疫苗不再仅依赖进口。但因为董事会成员拥有一票否决权，这个举措在当时并未遭受质疑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728172154a6c5b2ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728172154a6c5b2ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2413666426.HKD","BK4567","LU1165135440.EUR","IE00BN0W2V16.EUR","LU1721428933.USD","BK4588","BK4139","LU1543694498.USD","LU0347712357.USD","BK4121","LU2092937221.SGD","LU2089279066.USD","LU2041044095.USD","LU2229751404.USD","SVA","IE00BN0W2W23.USD","BK4585","IE00BN0W2T93.GBP","LU2413666699.HKD","A"],"gpt_icon":0},{"id":"2554715130","title":"89億美元鉅額派息背後：科興生物九年「內鬥」將如何收場？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554715130","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554715130?lang=zh_tw&edition=fundamental","pubTime":"2025-07-26 14:51","pubTimestamp":1753512672,"startTime":"0","endTime":"0","summary":"因为一场巨额分红，科兴生物重回舆论焦点。7月10日，科兴生物宣布，来自赛富基金的阎焱当选为董事会主席。对于上述情况，7月9日，科兴生物另一个以李嘉强为代表的董事会称，此次股东大会“不合法”。光鲜的另一面是自2016年宣布美股私有化计划以来，科兴生物已陷入“内斗”九年。判决书显示，杭州强新生物科技有限公司判将非法占有的厦门未名34%股权返还至未名医药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726150839a4646a7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726150839a4646a7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2554878086","title":"李嘉強方面表態：探索科興生物未來在港交所上市，自己無意長期擔任董事長職位","url":"https://stock-news.laohu8.com/highlight/detail?id=2554878086","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554878086?lang=zh_tw&edition=fundamental","pubTime":"2025-07-25 03:09","pubTimestamp":1753384144,"startTime":"0","endTime":"0","summary":"近日，关于科兴生物的控制权争议出现新进展。据了解，现任董事会已于7月15日向纳斯达克提交合规整改方案，解决科兴生物控股退市风险。另据接近李嘉强方面的知情人士表示，现任董事长李嘉强无意长期担任董事长职位，愿意在未来只保留董事席位，前提是科兴生物控股组成一个符合公司发展且具有治理经验的董事会，确保科兴普通股股东能有公平的待遇，尽快终结科兴的纷争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725031154a461c650&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725031154a461c650&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2553206188","title":"知情人士：解決科興「內鬥」應以談為主 科興生物董事長李嘉強稱尹衞東是個好CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2553206188","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553206188?lang=zh_tw&edition=fundamental","pubTime":"2025-07-24 17:53","pubTimestamp":1753350790,"startTime":"0","endTime":"0","summary":"谈及科兴创始人之一的尹卫东，上述知情人士称，李嘉强与其已认识十五年。据了解，中间打官司的这些年，两人也有见面，围绕科兴的治理问题，双方所代表的董事会有利益冲突，也有过一些误解，但李嘉强还是认为“尹卫东是一个很好的CEO”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072417550494b8039a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072417550494b8039a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2553283847","title":"【愛建醫藥】創新藥主線強勢迴歸，關注BigPharma管線價值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2553283847","media":"爱建证券研究所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553283847?lang=zh_tw&edition=fundamental","pubTime":"2025-07-22 09:23","pubTimestamp":1753147434,"startTime":"0","endTime":"0","summary":"WEEKLY REPORT创新药主线强势回归，关注BigPharma管线价值重估-爱建生物医药行业周报-本报告发布于2025年07月21日投资要点：医药板块跑赢沪深300，创新药再度强势回归。创新药主线强势回归、关注BigPharma管线价值重估。创新药再度领涨，仅线下药店回调。本周创新药出海主线强势回归，我们看好的PD-1双抗、ADC出海核心赛道均有亮眼表现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095530a6b97362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095530a6b97362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688271","06821","688180","BK4585","BK4588","688331","BK4139","01093","01877","LU2417539215.USD","688114","LU0109394709.USD","01276","SBHMY","LU0320765992.SGD","01541","LU2236285917.USD","SVA","600276","688293","TIL","688133","LU0889565916.HKD","09926","02157","09995","BK4007","02359","02696","BK4505","BK4568","688520","LU2456880835.USD","603259","02268","688301","688062","688105","688131","09606","AZN","LU1829250122.USD","LU2462157665.USD","01177"],"gpt_icon":0},{"id":"2553554408","title":"科興生物爭奪記：誰能打開百億美元「金庫」大門？","url":"https://stock-news.laohu8.com/highlight/detail?id=2553554408","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553554408?lang=zh_tw&edition=fundamental","pubTime":"2025-07-21 22:41","pubTimestamp":1753108869,"startTime":"0","endTime":"0","summary":"经过股东多年缠斗，科兴生物如同一座埋藏着百亿美元的金库。今年7月，科兴生物突然宣布向全体股东派发总额74.48亿美元分红，首期每股55美元将在前述特别股东大会召开前“闪电”支付；二、三期合计最高每股124美元。根据科兴生物方面7月10日发布的信息，每股普通股55美元的特别现金股息已在向科兴生物的合法股东派发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721224208a6b864d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721224208a6b864d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2552896634","title":"十年內鬥未休，科興生物滑向退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552896634","media":"法治日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552896634?lang=zh_tw&edition=fundamental","pubTime":"2025-07-17 19:45","pubTimestamp":1752752737,"startTime":"0","endTime":"0","summary":"7月16日，在科兴生物美股退市警报拉响之际，市场传出其正谋求港股上市的消息。在新冠疫情期间，凭借克尔来福疫苗全球接种量超28亿剂，科兴生物成为了“赢家”。由于科兴生物长期陷入内斗，审计机构出于风险考量早已撤离，这一状况直接导致科兴生物2024年年报至今难产。停牌超过6年的科兴生物，早已元气殆尽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717195029a6afc35d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717195029a6afc35d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2551126212","title":"科興「宮鬥」背後，第一大股東強新資本的算盤","url":"https://stock-news.laohu8.com/highlight/detail?id=2551126212","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551126212?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 21:59","pubTimestamp":1752674397,"startTime":"0","endTime":"0","summary":"目前，李嘉强控制的强新资本与关联公司持有科兴生物约三分之一的股份，是科兴生物的第一大股东。接近此事件的人士表示，他希望终结这场“宫斗”的一个重要的原因，是为了转移精力，推动强新科技原创药的研发上市。目前尚不清楚强新科技未来是否会寻求新的资本。2022年，潘爱华入狱，李嘉强正式踏入科兴股权争夺的中心。目前，双方的争议仍在持续中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162200499544f1a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507162200499544f1a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2551125501","title":"科興生物內鬥漩渦：九年紛爭何時落幕？又將走向何方？","url":"https://stock-news.laohu8.com/highlight/detail?id=2551125501","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551125501?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 20:59","pubTimestamp":1752670759,"startTime":"0","endTime":"0","summary":"另据上述知情人士透露，科兴生物小股东部分的分红已基本到账；大股东及争议股份对应款项暂存共管账户。市场对于强新资本方增持科兴生物的目的以及合法性争议。在2016年3月，科兴生物宣布其通过了“毒丸计划”。然而，2025年4月22日，科兴生物管理层发表声明称，目前董事会与英国枢密院裁决确认的名单并不相符。值得注意的是，科兴生物于2019年2月22日宣布，收到纳斯达克发出的暂停交易通知。自此以来，科兴生物已经停牌超过6年之久。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716210300a44ed16b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716210300a44ed16b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2550990429","title":"科興生物75億美元「清倉式派息」背後：十年內鬥掏空現金儲備 研發停滯退市風險激增","url":"https://stock-news.laohu8.com/highlight/detail?id=2550990429","media":"华夏时报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550990429?lang=zh_tw&edition=fundamental","pubTime":"2025-07-12 20:10","pubTimestamp":1752322248,"startTime":"0","endTime":"0","summary":"【科兴生物75亿美元“清仓式分红”背后：十年内斗掏空现金储备 研发停滞退市风险激增】被资本市场称为“疫苗行业世纪对决”的博弈，在7月9日加勒比海岛国安提瓜和巴布达的特别股东大会上达到高潮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507123455332375.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507123455332375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","SVA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}